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Poulsen PB1, Dollerup J1, Keiding H2
1Pﬁzer Denmark, Ballerup, Denmark, 2University of Copenhagen,
Copenhagen, Denmark
OBJECTIVES: From a Danish perspective to analyse the incre-
mental cost-effectiveness of the pharmacological smoking cessa-
tion therapy including counselling using varenicline (Champix®)
compared with bupropion SR (Zyban®), nicotine replacement
therapy (NRT) or smoking cessation courses (group based coun-
seling). METHODS: A Markov model was developed using a
hypothetical Danish cohort of smokers who made a single quit
attempt (cycle length 1 year). The direct costs of smoking cessa-
tion and treatment of smoking-related diseases (COPD, lung
cancer, CHD, stroke and asthma exacerbations) were included
(2006-prices). Future costs were discounted at 5%. The incre-
mental cost-effectiveness was calculated as costs per quitter and
costs per QALYs gained. The evidence for quit rates included
head-to-head trials for varenicline versus bupropion, a Cochrane
review of NRT (Stead et al., 2008) and a Danish cohort study of
smoking cessation courses (Kjaer et al., 2007). The time horizons
applied were 20-year and lifetime. RESULTS: Modelling results
revealed that varenicline resulted in more quitters and fewer
cases of smoking-related diseases. In a 20-year time horizon
(lifetime) cumulative QALYs gained using varenicline were 1,04
(4237) compared with smoking cessation courses, and up to
2517 (5600) QALYs compared with NRT. The costs per addi-
tional quitter using varenicline instead of bupropion were
DKK3060 (20-year), whereas varenicline was cost-saving com-
pared with NRT and smoking cessation courses. With a lifetime
perspective varenicline was always a cost-saving option in terms
of cost per quitter. Resulting in more QALYs and fewer costs
varenicline dominated the other alternatives, when lifetime was
considered. With a 20-year time horizon, the costs per QALY
gained for varenicline versus bupropion were DKK30,272, but
varenicline still dominated NRT and smoking cessation courses.
CONCLUSIONS: This cost-effectiveness analysis conﬁrms that
varenicline is a cost-effective strategy for smoking cessation in
Denmark. This ﬁnding is in accordance with results found in
Sweden and The Netherlands.
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COST OF ALLERGIC RHINITIS IN PEDIATRIC PATIENTS
IN MEXICO
Del-Rio Navarro B1, Reyes-Lopez A1, Lemus A2
1Federico Gomez Mexican Children Hospital, Mexico City, Mexico,
2Sanoﬁ aventis de México, Mexico City, D.F, Mexico
OBJECTIVES: To estimate the direct and indirect costs of aller-
gic rhinitis (AR) in pediatric patients from the perspective of
patient’s family. METHODS: 195 patients (children/adolescents)
from a third-level public pediatric hospital that do not belong
to social security system were included in this retrospective,
cross-sectional cost-of-illness study. Information of demographic
characteristics, frequency and severity of illness, consultations,
diagnostic tests, out-of-pocket-expenditure for medication,
transportation, food and house refurbishment as well as absence
from work of caregivers and school absenteeism of patients was
collected with a standardized questionnaire. Additionally, the
corresponding clinical records were reviewed to conﬁrm the pre-
scribed medications and the sickness evolution. Country level
costs were obtained applying recent prevalence estimates of AR.
RESULTS: The average annual costs per children are €264.96.
Assuming that AR prevalence in this age group ranges from
18.5% to 42.1%, the costs of AR in Mexico range from €623.52
to €1,418.92 millions annually. For adolescents the average
annual costs per patient are €278.81, assuming AR prevalence
goes from 21.3% to 41.3%, the country level costs range from
€640.61 to €1242.11 millions annually. For both age groups
direct costs are responsible for 97.4% and 98.7% of the expen-
ditures respectively, being medications the main cost driver.
Antihistamines represent 38.1% and 33.6% of the medication
costs for children and adolescents respectively. House refurbish-
ment was the most relevant cost factor within nonmedical direct
costs, however, only 30% of the caregivers mentioned had had
this type of expenditure. There was no difference in costs accord-
ing to illness severity, although the school absenteeism was
twofold in children. CONCLUSIONS: The economic burden of
AR in Mexico is important since 50% of health expenditure
comes from out-of-pocket. Nevertheless these results could
underestimate the real cost of illness because parents not neces-
sarily accomplish the recommendations of pediatricians related
to medications and house refurbishment.
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ESTIMATING EXCESS COSTS OF POPULATION-BASED CASES
WITH MILD COPD—RESULTS FROMTHE KORA F3 STUDY
Menn P1, John J1, Heinrich J2, Döring A2, Brüske-Hohlfeld I2, Holle R1
1Institute of Health Economics & Health Care Management,
Helmholtz Center Munich, Neuherberg, Germany, 2Institute of
Epidemiology, Helmholtz Zentrum Munich, Neuherberg, Germany
OBJECTIVES: Chronic obstructive pulmonary disease (COPD)
is a common chronic condition that has many systemic effects
beyond pulmonary problems alone.Our objectivewas to calculate
direct medical excess costs of COPD. METHODS: Data from the
population-based KORA survey conducted in the region of Augs-
burg in 2004/05 were used to calculate excess costs of COPD.
Data were available for 200 subjects with and 2984 subjects
without COPD. Diagnosis of COPD was based on questions on
chronic cough for more than three months a year. Direct medical
costs were calculated based on self-reported resource use with
regard to physician visits, hospital stays, rehabilitation and drug
consumption. To adjust for age differences between participants
with and without COPD, controls that matched subjects with
COPD in terms of age and sex were randomly sampled from those
without COPD. To value utilization, recommended national unit
costs were inﬂated to 2005 price levels. RESULTS: Costs were
signiﬁcantly higher in subjects with COPD with regard to total
costs, drugs and physician visits (p < 0.0001), but not for hospital
stays. With these mild cases, no excess costs of rehabilitation were
observed. Preliminary analyses showed total direct medical excess
costs for COPD of about €900 per year, the largest contribution
coming from drug consumption (€600). CONCLUSIONS: Total
direct medical costs are higher for subjects with COPD, and two
thirds of these excess costs are due to the use of medications.
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THE HOSPITALIZATION COST OF PATIENTS WITH CHRONIC
OBSTRUCTIVE PULMONARY DISEASE (COPD) INTHE
UNIVERSITY HOSPITAL OF ALEXANDROUPOLIS, GREECE
Hatzikou M1, Ravikalis V2, Steiropoulos P3, Geitona M1, Bouros D3
1University of Thessaly,Volos, Greece, 2University of Alexandroupolis,
Alexandroupolis, Greece, 3University Hospital of Alexandroupolis,
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INTRODUCTION: Patients with COPD consume considerable
health care resources due to their lung disease and frequent
comorbidities.OBJECTIVES:To estimate the hospitalisation cost
of patients suffering fromCOPD in the department of pneumonol-
ogy of the university hospital of Alexandroupolis, Greece.
METHODS:The study sample consisted of all the patients, 142 in
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total, with COPD, of all stages, who were hospitalized in the
pneumonology department, in 2006 and 2007. The analysis was
performed retrospectively. Information on mean treatment cost
per patient is presented separately for the I-IV COPD stages,
according to GOLD criteria. Direct cost analysis was based on
cost of personnel of the clinic, medication, laboratory and imaging
tests. The economic analysis did not include the depreciation of
capital assets as well as the overhead cost. The prices used for the
analysis were based on Greek NHS prices (FEK157/91, A’ issue),
2006 Euros. RESULTS: The mean (SD) length of stay in the
deparment of pneumonology for a COPD patient was 6 (4) days
and the mean(SD) actual cost per patient with stage I COPD was
€1091 (85), the mean cost for a patient with stage II COPD was
estimated at €1081 (106.5) for the thewhole length of stay and the
mean cost for stage III and IVCOPDpatients are 1146 (120,3) and
€1222 (197), respectively. CONCLUSIONS: COPD posses a con-
siderable economic burden to health care systems and societies.
These ﬁndings are in accordance to international literature.
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COMPARISON OF OUTPATIENT AND INPATIENT COSTS OF
MODERATE AND SEVERE EXACERBATIONS OF COPD IN
POLAND IN 2007
Jahnz-Rózyk K,Targowski T, Mierzejewska MJ, From S
Military Institute of Health Service,Warsaw, Poland
OBJECTIVES: Assessment of direct and indirect costs of COPD
exacerbations under usual clinical practice in primary and second-
ary care from societal perspective in Poland METHODS: An
observational, prospective study was conducted among patients
with exacerbation of moderate or severe COPD. All patients
(n = 197) were divided into two groups depending on place of
care. The group treated in hospital care (HC) and in ambulatory
care (AC) adequatly oconsisted of 89 and 108 patients. The direct
costs included cost of drugs, diagnostic tests, inhospital and
outpatient care.We singled out one-day medical treatment facility
costs for inpatients. The indirect costs included costs of work days
lost. RESULTS: The mean duration of COPD exacerbation did
not differ signiﬁcantly between the groups (p > 0.5, adaquately
9.5 and 8.8 days for HC and AC group). The total health care cost
per exacerbation was €1410,0 (5078.50 PLN) in secondary care
(the HC group) and it was 10.5 times higher than the total cost of
exacerbation in primary care (the AC group) €134,3 (483.80
PLN) (according to course of currencies on 15 December 2007).
The costs of drugs and diagnostic tests were signiﬁcantly higher in
the HC group than in the AC group, however it were facility costs
of inhospital stay and medical visits in the HC group that inﬂu-
enced expenditures related to COPD exacerbations most tremen-
dously, as they were 27 times higher than in the AC group.
CONCLUSIONS: In Poland the costs of COPD exacerbation
managed in secondary care are 10.5-fold higher than in primary
care. Therefore, the decisions about admission of patients with
COPD exacerbation to hospital should be made carefully.
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OBJECTIVES: To estimate differences in total payments for
treatment and resource utilization among patients with COPD
over a one-year period following initiation of treatment with
albuterol MDI (ALB) or levalbuterol MDI (LEV) in usual prac-
tice in the United States. METHODS: MarketScan® data were
used to identify 46,454 COPD patients age > 5 who ﬁlled a new
prescription for ALB or LEV between October 1, 2003 through
September 30, 2006 and met other study inclusion/exclusion
criteria. Multivariate methods were used to adjust for differences
in potential confounders across treatment groups, such as patient
age, gender, COPD severity score, Charlson comorbidity score,
prescribing physician specialty, patterns of other respiratory drug
use, and geographic region. Given the eminent ban (effective
January 1, 2009) on MDIs using CFC propellant, in addition to
actual claims payments, hypothetical “HFA-propellant-only”
claims payments, calculated by replacing payment rates for CFC
drugs with payment rates for HFA versions of the same drugs,
also are analyzed to enhance the applicability of study results
to the post-CFC environment. RESULTS: Total payments for
LEV patients were $2769 higher (p < 0.001) compared to ALB
patients. Total payments for LEV patients were $2467 higher
(p < 0.001) than hypothetical ALB-HFA-only patients. Payments
for respiratory drugs were higher for LEV patients ($673,
p < 0.001; projected HFA-only payments $515; p < 0.001).
There was no statistically signiﬁcant difference between ALB and
LEV patients in risk of hospitalization (OR = 1.033, p = 0.56)
or frequency of ED visits (IRR = 0.99, p = 0.80). However,
LEV patients had a higher frequency of total outpatient visits
(IRR = 1.13, p < 0.001) and COPD-related outpatient visits
(IRR = 1.17, p < 0.001). CONCLUSIONS: COPD patients using
LEV had higher total payments and respiratory drug payments
compared to ALB patients. LEV patients had more frequent
outpatient visits. There was no consistent, statistically signiﬁcant
association between treatment and either likelihood or frequency




RATES OF DISCONTINUATION AMONG COMMONLY
PRESCRIBED MEDICATIONS INTHE US
Vanelli MR, Pedan A, Messier D, Hoar J, Liu N, Kiarsis K
Adheris, Inc, Burlington, MA, USA
OBJECTIVES: To measure relative rates of discontinuation
among commonly prescribed chronic disease medication classes
under conditions of routine care. METHODS: De-identiﬁed
pharmacy records for 1.99 million patients who received medi-
cation from retail pharmacy chains throughout the United States
were used to select patients who obtained a ﬁll between January
1, 2007 and January 30, 2007 for any of the following medica-
tion classes: antidepressants (n = 339,059); bisphosphonates
(n = 120,098); cardiovascular agents (n = 622,947); glaucoma
medications (n = 48,229); statins (n = 452,978); inhaled steroids
(n = 95,900); insulins (n = 66,637); and oral antidiabetic agents
(n = 248,280). The primary outcome measure was the median
time-to-discontinuation (TD50). Kaplan-Meier analysis was used
to estimate the risk of discontinuation over the subsequent 360
days for both “inexperienced” and “experienced” groups of
patients. Inexperienced patients were deﬁned as those who had
not been dispensed an in-class medication in the prior 180 days;
experienced patients were those who had been. Discontinuation
was deﬁned as being 30 days late for a scheduled reﬁll. Patients
switched to an in-class medication were considered to have
continued therapy. RESULTS: Median days to discontinuation
(TD50) among patients who had not ﬁlled a prescription for an
in-class medication in the prior 180 days were: inhaled steroids
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